Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)

May 21, 2026 6:37 AM
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $34.00 price target on Roivant Sciences (NASDAQ: ROIV).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments